MB-106

N/A

Report date: 2026/02/11 20:01:36

Base Information

Drug NameMB-106
Drug Alias NameMB-106
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaAutoimmune DiseasesWaldenstrom Macroglobulinemia +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio IncFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaAutoimmune DiseasesLymphoma, Mantle-Cell +[11] 
Inactive IndicationsWaldenstrom Macroglobulinemia

Other Information

ATC CodeN/A
Related LinksN/A